Genome Engineering with TAL-Effector Nucleases and Alternative Modular Nuclease Technologies

Author(s): Andrew M. Scharenberg, Philippe Duchateau, Julianne Smith

Journal Name: Current Gene Therapy

Volume 13 , Issue 4 , 2013

Become EABM
Become Reviewer
Call for Editor


Over three years following the discovery of the TAL code, artificial TAL effector DNA binding domains have emerged as the premier platform for building site-specific DNA binding polypeptides for use in biological research. Here, we provide an overview of TAL effector and alternative modular DNA binding domain (mDBD) technologies, focusing on their use in established and emerging architectures for building site-specific endonucleases for genome engineering applications. We also discuss considerations for choosing TAL effector/mDBD or alternative nuclease technologies for genome engineering projects ranging from basic laboratory gene editing of cultured cell lines to therapeutics. Finally, we highlight how the rapid pace of development of mDBD-based, such as monomeric TALENs (I-TevI-TAL), and more recently RNA-guided nucleases (CRISPR-Cas9) has led to a transition in the field of genome engineering towards development of the next generation of technologies aimed at controlling events that occur after targeted DNA breaks are made.

Keywords: DNA repair, double strand break, exonuclease, genome engineering, homing endonuclease, meganuclease, nuclease, TALEN, ZFN, zinc finger nuclease.

open access plus

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Published on: 18 July, 2013
Page: [291 - 303]
Pages: 13
DOI: 10.2174/15665232113139990026

Article Metrics

PDF: 110